Valeo Financial Advisors’s Ligand Pharmaceuticals LGND Stock Holding History

Valeo Financial Advisors’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-624	Closed	-$44K	–	1897
2020 Q2	$44K	Buy	624 +10	+2%	+$634	﹤0.01%	777
2020 Q1	$32K	Hold	614	–	–	﹤0.01%	748
2019 Q4	$40K	Sell	614 -27	-4%	-$1.8K	﹤0.01%	726
2019 Q3	$40K	Hold	641	–	–	﹤0.01%	672
2019 Q2	$46K	Buy	+641	New	+$47.2K	0.01%	631
2019 Q1	–	Sell	-37	Closed	-$3K	–	1599
2018 Q4	$3K	Sell	37 -16	-30%	-$1.71K	﹤0.01%	1210
2018 Q3	$6K	Sell	53 -2	-4%	-$302	﹤0.01%	1134
2018 Q2	$8K	Hold	55	–	–	﹤0.01%	1015
2018 Q1	$6K	Sell	55 -3	-5%	-$297	﹤0.01%	1080
2017 Q4	$5K	Buy	+58	New	+$5.03K	﹤0.01%	1009

Other funds holding LGND

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CCMLC

Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

CCA

Conestoga Capital Advisors Wayne, Pennsylvania $4.6B AUM 16.08% 1-Year Est. Return

SDJVC

St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return

Valeo Financial Advisors's LGND Position: Q3 2020 in Review

Valeo Financial Advisors sold out of Ligand Pharmaceuticals (LGND) in Q3 2020, closing a stake of 624 shares — an estimated $44K sold.

Valeo Financial Advisors first reported a position in LGND in Q4 2017 and held it in 10 quarters. The position peaked at $46K in Q2 2019. 252 funds tracked by Wall St. Rank hold LGND as of Q3 2020.

Valeo Financial Advisors reported no remaining Ligand Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
Valeo Financial Advisors sold 624 Ligand Pharmaceuticals shares in Q3 2020, an estimated $44K.
Valeo Financial Advisors first reported a position in Ligand Pharmaceuticals in Q4 2017 and held it in 10 quarters.
Valeo Financial Advisors's Ligand Pharmaceuticals position peaked at $46K in Q2 2019.
252 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q3 2020.

Based on Valeo Financial Advisors's 13F filing for Q3 2020, filed 28 Oct 2020.